Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients.

valve in valve

The VIVA (Valve in Valve) registry, conducted at 23 sites, was a prospective study designed to systematically collect data from patients with degenerated surgical prostheses who underwent transcatheter aortic valve replacement.

Researchers enrolled a total of 202 patients with degenerated surgical prostheses who were eligible for elective treatment with CoreValve or CoreValve Evolut R.


Read also: Aspirin in Primary Prevention: Another “Trendy” Topic in Publications.


Mean patient age was 79.9 years old and the risk according to the Society of Thoracic Surgeons score was 6.6%.

Although 41.8% of patients had ≤21-mm surgical bioprostheses, valve hemodynamic parameters markedly improved from baseline (mean baseline valve gradient 35.0 ± 16.3 mmHg vs. 17.5 ± 8.6 mmHg at discharge). At 1 year, aortic regurgitation greater than mild was barely 1.1%.

Clinical events at 30 days demonstrated low mortality (2.5%), no disabling strokes, a 0.5% rate of acute kidney injury, and an 8% rate of permanent pacemaker implantation.

At 1 year, the mortality rate remained low (8.8%), with only 1 disabling stroke during that period (0.6%).


Read also: Pulmonary Hypertension: No Reason for TAVR Contraindication.


About 2.5% of patients (n = 5) experienced coronary artery occlusion as complication (one of the most feared for valve-in-valve); 3 took place during release, 1 immediately after the procedure, and only 1 several months later.

Conclusion

Surgically-implanted valves with bioprosthetic degeneration can be safely treated with the self-expanding device with more evidence in the market, which has excellent 1-year clinical and hemodynamic outcomes in this real-world non-selected population.

Orginal Title: TAVR for Failed Surgical Aortic Bioprostheses Using aSelf-Expanding Device 1-Year Results From the Prospective VIVA Postmarket Study.

Reference: Didier Tchétché et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....